KMT2A and B-cell acute lymphoblastic leukemia: Particularly, antileukemic activity of pyrvinium was observed in pediatric MLL-rearranged AML, B-cell acute lymphoblastic leukemia (ALL), and T-ALL with NOTCH inactivation signature [58–60].